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Parkinson’s disease (PD) is a chronic progressive neurodegenerative 
disorder characterised by bradykinesia, rigidity, resting tremor and 
postural instability resulting from a central nervous system dopamine 
deficiency. Worldwide it is a common disorder, affecting 1 - 2% of 
the population aged >60 years.[1] The prevalence may rise to 4% in 
higher age groups in Western countries, but the prevalence of the 
disease in Africa was reported to be much lower at 7 - 43/100 000.[2] 
This low prevalence in the black African population is supported by 
studies comparing the prevalence between an American population 
(341/100 000), a Nigerian population (67/100 000) and a Tanzanian 
population (40/100 000). The reasons for these observations are 
still unclear, but environmental factors, shorter life expectancy and 
undiagnosed disease may play a role.[3,4] Whereas no epidemiological 
studies on PD in South Africa (SA) are available, the impression 
among practising neurologists is certainly that PD is seen more 
commonly in the white population. The low prevalence in black 
populations may be related to genetic factors. During the past decade, 
increasing evidence that genetic factors play an essential role in the 
development of PD has emerged. About 10% of patients with PD 
show a Mendelian pattern of inheritance, with several genes being 
identified as having a causal relationship;[5] these include SNCA, 
parkin, DJ-1, PINK1, LRRK2, VPS35 and EIF4G1.
Studies from Africa that have looked at an association between 
PD and gene mutations are limited, and this report describes the 
clinical findings of a group of black SA patients with PD who were 
screened for copy number variation (CNV) mutations in the known 
PD-causing genes. Whole-exon deletions or duplications, primarily 
in the parkin gene, are a common cause of PD and have been found 
in both familial and sporadic forms of the disorder.[6]
Methods
All black African patients with a diagnosis of PD who were being 
followed up at the neurology clinic at Steve Biko Academic Hospital, 
Pretoria, SA, were included in the study. The patients were invited to 
participate in the study, and informed consent and ethical committee 
approval of the University of Pretoria (Ref. No. 128/2012) were 
obtained. The patients were evaluated by a clinician proficient in 
the neurological examination of patients with PD to confirm that 
they met the UK Parkinson’s Disease Society Brain Bank clinical 
diagnostic criteria for PD. History and demographic data were 
obtained, and after a full neurological examination, symptoms were 
scored according to the Unified Parkinson’s Disease Rating Scale 
(UPDRS). Atypical features were noted and patients were classified 
according to age at onset, cognitive functioning and motor features.
Venous blood (20 mL) was obtained and genomic DNA was 
extracted. The multiplex ligation-dependent probe amplification 
(MLPA) method was used for detection of CNV mutations. 
Specifically, the commercially available SALSA P051-D1 Parkinson 
kit (MRC-Holland, Netherlands) was used. This kit contains probes 
for all exons of genes in which PD-causing CNV mutations have 
previously been found, including parkin, PINK1, DJ-1 and SNCA. In 
addition, the kit contains probes for detection of two point mutations, 
G2019S in LRRK2 and A30P in SNCA. The MLPA experiments were 
performed according to the manufacturer’s instructions and the 
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amplified products were analysed on 
a 3130xl Genetic Analyser (Applied 
Biosystems, USA). Coffalyser. Net 
software (v14072.1958, MRC-Holl-
and, Netherlands) was used for copy 
number calculations.
Results
Sixteen black patients with PD were 
identified (9 males and 7 females), 
2 of them siblings. Most patients 
were Sotho speakers (9/16), the rest 
speaking Zulu or Ndebele. Their ages 
ranged from 56 to 82 years (mean 68), 
disease duration from 1 to 21 years 
(mean 6.8) and age of onset of the 
disorder from 50 to 74 years; a 
family history of PD was obtained 
in 3 patients (19%), the 2 siblings 
and 1 other patient. Classification 
according to motor features showed 
44% to be mixed, 31% akinetic-rigid 
and 25% tremor-dominant subtypes. 
UPDRS scores when on medication 
ranged from 7 to 88; tremor graded 
according to the UPDRS was  scored 
as 1 (slight and infrequent) in 4 parti-
cipants (25%), 2 (mild and imper-
sistent) in 6 (38%), 3 (moderate and 
mostly present) in 4 (25%) and 4 
(marked and mostly present) in 2 
(13%). The rigidity score was 1 in 
25%, 2 in 50% and 3 in 25%, and 
the bradykinesia score was 1 in 44%, 
2 in 25%, 3 in 13% and 4 in 19%. 
Cognitive screening using the mini-
mental state examination (MMSE) 
showed normal cognition in 40% 
and minimal cognitive impairment 
in 40%, while 20% had dementia. 
Patients with cognitive impairment 
showed a greater mean rigidity score 
(2.33) as derived from the UPDRS 
than patients without dementia (1.5). 
Interestingly, hyperreflexia was found 
in 7/16 patients (44%), and slowing 
of saccadic eye movements was seen 
in 2. The clinical findings are set out 
in Table 1.
Genetic screening was performed 
on 11 unrelated patients for whom 
DNA was available. Importantly, both 
the G2019S LRRK2 and A30P SNCA 
mutations were excluded as a cause 
of the disorder in all the patients. 
In 10 patients, no CNV mutations 
were found; however, in one patient a 
heterozygous deletion of parkin exon 
4 was identified. This patient (Table 
1, patient 4) had an age of onset of 
50 years with no family history of 
the disorder. In addition to the signs 
of PD, she was also noted to have T
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hyperreflexia with bilateral Hoffmann’s reflexes, but normal plantar 
responses. No dystonia was noted, and a computed tomography scan 
of the brain did not show any focal lesions.
Discussion
PD is one of the commonly occurring neurodegenerative disorders, 
yet little information about this disease in black African patients is 
available and clinical and genetic studies involving these patients are 
limited.
It is well known that PD is mainly seen in older individuals, with 
the incidence rising with every decade of age; worldwide, ~4 - 10% 
of patients have early-onset disease.[7] Compared with patients with 
PD from Zambia, in whom the mean age of onset was 54 years,[8] and 
a group of 18 black SA patients with PD with a mean age of onset of 
52 years,[9] our patients’ mean age of onset at 62.5 years was slightly 
older; it is, however, comparable to the average age of onset of 62 years 
in Western studies. There were no patients with young-onset (defined 
as <50 years) PD in our group, but this may be a reflection of the small 
sample size.
Clinical classifications of motor subtypes in PD in Western 
population studies show a mixed subtype of disease as the most 
common presentation (66%), followed by the akinetic-rigid subtype 
(26%) and lastly the tremor-dominant group (8%).[10] Our patients 
showed a similar pattern, but the tremor-dominant group was larger 
at 25%. This is comparable to a group of Nigerian patients with PD, 
55% of whom had mixed disease, 32% tremor-dominant disease and 
14% the akinetic-rigid form.[11] Eventually this may have prognostic 
implications, as some studies have shown that patients with tremor-
dominant disease may have a more favourable course.[12]
Cognitive impairment and dementia may occur in patients with 
PD, especially after long disease duration. Generally, patients with PD 
have an almost six-fold increased risk of developing dementia, and up 
to 24 - 31% have cognitive impairment.[13] Of our group of patients, 
20% had dementia; these patients all also had high UPDRS scores 
(>35). Severe motor disorders such as rigidity and gait instability have 
been linked to an increased probability of developing dementia, and 
this appeared to be the case in our patients, among whom the mean 
rigidity score was high in those who were cognitively impaired (2.33 
v. 1.5 in non-demented patients), but larger numbers of patients need 
to be studied to confirm this association. An older age at disease 
onset was not found to be a risk factor for dementia in our study (ages 
50, 60 and 51 years at disease onset in the patients with dementia). 
Disease duration, age of onset and motor symptom severity have 
been found to be risk factors in some studies, but others have not 
confirmed these associations.[14]
There is currently increasing evidence that genetic factors are 
important in the development of PD, and up to 10% of cases are 
believed to have a genetic cause. Genes associated with an autosomal 
dominant pattern of inheritance include SNCA and LRRK2, while 
autosomal recessively inherited gene abnormalities include parkin, 
DJ-1, PINK1 and ATP13A2.[5] Whereas SNCA and parkin mutations 
are usually associated with early-onset PD, LRRK2 mutations, 
specifically the G2019S mutation[15] (which was not found in our 
study), are the most frequent cause of late-onset familial and sporadic 
PD. A positive family history was found in up to 2.4% of black 
African patients in case series,[16] and one SA study of a mixed group 
of patients found an overall positive family history in approximately 
one-third of individuals with late-onset PD.[9]
Conclusion
Although the number of patients in our study was small, three 
reported a positive family history, and only one of the patients (who 
had reported no family history) had a pathogenic CNV mutation in 
the parkin gene. As parkin is associated with an autosomal recessive 
form of PD, further studies are warranted to possibly identify a 
second pathogenic mutation in this patient.
To date, only two black SA patients have been shown to harbour 
mutations in the parkin gene and none have had mutations in any 
of the other PD-causing genes.[17,18] These findings suggest that 
unravelling the genetics of PD is still only in the early stages, and 
further studies for new candidate genes are needed. Future studies 
will involve whole-exome sequencing of DNA from our patients to 
identify defects in potentially novel PD-causing genes.
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